Introduction
Small amyloid deposits of structurally unstable transthyretin (TTR) fibrils have been found in autopsies of 14 to 25% of elderly individuals depending on patient selection and amyloid detection methodology employed.
1,2 When wild-type TTR (TTRwt) is deposited in greater amounts in the heart leading to clinical manifestation, wild-type transthyretin amyloidosis (ATTRwt), also known as senile systemic amyloidosis, is said to be present. 3 In contrast to other forms of amyloidosis, ATTRwt almost exclusively affects the heart, with the exception of carpal tunnel syndrome (CTS) 3, 4 and lumbar spinal canal stenosis. 5 Patients affected by ATTRwt can suffer from heart failure (HF), arrhythmias 6 and other common cardiac manifestations including angina. 3, 4 The first series of ATTRwt with clinical manifestations was published in 1987. 7 Since then, however, studies describing the natural history and clinical characteristics of the condition have been few and included limited number of patients, from a small number of referral centres. 8, 9 Based on the available case series, ATTRwt has been traditionally considered a remarkably sex-specific disease 3, 4 with a very strong male predominance affecting only patients over 60 years old. 3, 4 The accepted ATTRwt clinical phenotype also includes concentric left ventricle (LV) hypertrophy, preserved left ventricular ejection fraction (LVEF) 3, 4, 9 and normal or low QRS voltages on ECG. 3, 4 Although the demonstration of TTR amyloid deposits on endomyocardial biopsy (EMB) plus the absence of mutations in the TTR gene remains the gold standard for the diagnosis of ATTRwt, 3, 4 in recent years, cardiac magnetic resonance (CMR) has been shown to be helpful in the work-up for cardiac amyloidosis 10 and scintigraphy with diphosphonate agents has been proven very useful in identifying patients with cardiac amyloidosis. 10, 11 Furthermore, non-invasive diagnostic criteria for cardiac ATTR amyloidosis based on technetiumlabelled bone scintigraphy and absence of a monoclonal protein in serum or urine have been proposed very recently. 12 Although the true prevalence of ATTRwt in the general population remains unknown, 4 we are witnessing a significant increase in the number of referred patients with the suspicion of ATTRwt and several recent reports suggest that ATTRwt could be the most frequent form of cardiac amyloidosis. 4, 13, 14 The need for a better delineation of ATTRwt clinical characteristics is stressed by the fact that diagnosing this disease should lead clinicians to avoid certain drugs and to screen patients for possible complications such as atrial arrhythmias and conduction disorders. 3, 4 Furthermore, several new therapies are under development for this condition, 4, 15, 16 some of which have shown promising preliminary results. 16, 17 In the context that ATTRwt diagnosis has clinical implications and that ATTRwt could soon be treatable, cardiologists should be familiar with the broad clinical spectrum of the disease in order to correctly identify it.
The purpose of this study was to describe the main clinical characteristics of a large cohort of patients with ATTRwt to better define the disease.
Methods
We conducted a descriptive study at two tertiary university hospitals in Bologna (Italy) and Madrid (Spain). Information from prospective local databases and clinical charts of all patients diagnosed with ATTRwt at both centres over a 16-year period (Bologna) and a 6-year period (Madrid) were reviewed.
Study patients
ATTRwt was diagnosed in the presence of (1) cardiac involvement and TTR deposits on tissue biopsy or (2) non-invasively, in the presence of: cardiac involvement defined as maximal left ventricular wall thickness > _12 mm, intense biventricular uptake (Perugini Score 2-3) on 99m Tc-DPD scintigraphy 18 and AL exclusion by serum and urine protein electrophoresis by immunofixation electrophoresis plus serum free light chain assay. 4, 12 In all cases, genetic testing confirmed the absence of mutations in the TTR gene.
Data collection
Demographic and clinical characteristics were collected at admission or at presentation at the outpatient clinic. Age, date of ATTRwt diagnosis and symptoms onset were obtained. The clinical profile leading to ATTRwt diagnosis was recorded as well as the previous diagnosis. Data regarding functional class according to New York Heart Association (NYHA), heart failure signs, admissions due to cardiovascular causes, blood pressure, and treatment at first evaluation were obtained. Hypertension was defined based on clinical history or use of, at least, one antihypertensive medication at presentation. Coronary artery disease (CAD) was defined by previous history of myocardial infarction or by the presence of at least moderate coronary stenosis by angiography. Left-sided valve disease was defined as the presence of moderate or severe regurgitation or stenosis by echocardiography according to current guidelines. The history of monoclonal gammopathy of undetermined significance (MGUS) or CTS was also collected.
Blood test parameters were collected from the first blood test available. Creatinine clearance was calculated using CKD-EPI formula and NT-proBNP was obtained when available.
Follow-up started at the time of diagnosis of ATTRwt. Information on patient's final status was obtained from medical records or from the primary care physicians. Overall mortality was defined as mortality due to any cause during follow-up. Cardiovascular mortality was considered if death was caused by heart failure, myocardial infarction or stroke. A committee formed by two physicians adjudicated these events. A third physician resolved discrepancies.
ECG
ECG measures were based on standard definitions using the first ECG available when the diagnosis of ATTRwt was made. Low voltage was assessed by limb or precordial criteria (QRS amplitude < _0.5 mV in all limb leads or < _1 mV in all precordial leads) 3, 10 and Sokolow index (< _1.5 mV). 19, 20 Electrocardiograhic LV hypertrophy was evaluated according to Sokolow criteria and voltage-to-mass ratio was calculated as peripheral QRS score divided by indexed LV mass. Ventricular-paced QRS complexes were excluded.
Echocardiography
Chamber and LVEF quantification was based on standard recommendations. 21 Patterns of hypertrophy were defined as previously described.
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LV mass was evaluated by M-mode and myocardial contraction fraction (MCF) was calculated. Tc-DPD-scintigraphy studies were performed and evaluated as described elsewhere. 14, 18 The scan was considered positive when it revealed a moderate to severe 99m Tc-DPD uptake (Perugini score 2-3) in both ventricles. 18 
Genotyping
All patients underwent genetic analysis for mutations in TTR gene. The coding regions of the TTR gene were amplified by polymerase chain reaction and amplified DNA fragments were directly sequenced.
Histology
Patients underwent cardiac, abdominal fat or salivary gland biopsies if considered by their treating physicians. Sections from formalin-fixed, paraffinembedded biopsy specimens were stained with Haematoxylin-Eosin and Congo Red. Immunostaining was performed using the following antibodies: monoclonal antibody directed against AA amyloid, TTR, k-light chain, and j-light chain (all from DAKO, Glostrup, Denmark). The specificity of immunostaining was controlled using specimens containing known classes of amyloid. Omission of primary antibodies served as negative controls. Mass spectrometry (MS) proteomic analysis was undertaken in selected cases.
Statistical analysis
Normality was assessed using Shapiro-Wilk test. Normally distributed variables were expressed as mean ± standard deviation while non-normally distributed variables were reported as the median and interquartile range (IQR). Categorical data were reported as frequencies and percentages and were compared using Chi squared or Fisher's exact test. Comparison of continuous variables between two independent groups was performed using unpaired Student's t-test (if normally distributed) or Mann-Whitney U-test (non-normally distributed variables) and in cases where more than two groups were compared, one way analysis of variance (ANOVA) or Kruskal-Wallis test was used. Survival was evaluated with Kaplan-Meier curves and hazard ratios were estimated by Cox proportional hazards regression. All tests were 2-tailed and a P value of <0.05 was considered to be statistically significant. Statistical analysis was performed using SPSS Statistics (version 22. IBM Corp., Chicago, IL, USA).
Results
During the study period, a total of 108 patients were diagnosed with ATTRwt, 71 at the University of Bologna (Italy) and 37 at Hospital Universitario Puerta de Hierro Majadahonda in Madrid (Spain). The findings from each centre are shown in Supplementary material online, Table S1 .
99m Tc-DPD scintigraphy and tissue biopsy ATTRwt was diagnosed by histology coupled with immunohistochemistry/MS in 67 patients (62%). A non-invasive diagnosis was made in 41 (38%) patients. In all cases, mutations in the TTR gene were excluded ( Table 1) .
Among patients with histologically proven ATTRwt, 65 (97%) had undergone EMB and just 2 (3%) showed the presence of amyloid in an extracardiac biopsy.
Except in three cases (all confirmed by EMB), all patients underwent 99m Tc-DPD scintigraphy. In all cases, the scan showed an intense (grade 2-3) biventricular uptake.
Patients diagnosed non-invasively were significantly older at time of symptom onset (82.7 ± 6.4 vs. 74.1 ± 7.2; P < 0.001) and diagnosis (84.2 ± 6.1 vs. 75.2 ± 7; P < 0.001) than patients diagnosed invasively. Patients diagnosed non-invasively also presented with worse renal function (45 ± 21 vs. 58.6 ± 21 mL/min/1.73 m 
Clinical features
Basal characteristics Twenty patients (18.5%) were female. Mean age at symptom onset was 77.3 ± 8 years and mean age at diagnosis was 78.6 ± 8 years.
Interestingly, female patients were significantly older than male patients at time of symptoms' onset (82.3 vs. 76.1; P = 0.002) as well as at diagnosis (83.9 vs. 77.4; P = 0.001). Women were also diagnosed non-invasively more frequently (75% vs. 29%; P < 0.001) and tended to present with a smaller LV cavity size (41 vs. 46 mm; P = 0.003), better LVEF (59 vs. 51%; P = 0.014), thinner LV ventricles and lower LV mass (158 vs. 212 g/m 2 ; P = 0.002). Findings comparing characteristics according to gender are shown in Supplementary material online, Table S3 .
Clinical profile leading to diagnosis
The clinical profile leading to ATTRwt diagnosis was heart failure (HF) in 73 cases (68%), including one patient (1%) diagnosed while being treated for cardiogenic shock.
Nevertheless, HF was not the unique presentation leading to diagnosis: 8 patients (7%) presented with symptomatic atrioventricular (AV) block, requiring a pacemaker; in 15 cases (14%), the diagnosis was reached as part of the work-up in the differential diagnosis of left ventricular hypertrophy (LVH), and 12 patients (11%) were diagnosed as an incidental finding after a positive DPD-scan requested for oncologic or rheumatologic reasons ( Table 1) .
Comorbidities
Regarding comorbidities, 59 (55%) patients were previously diagnosed with hypertension, 14 patients (13%) had history of CAD and 10 (9.3%) had moderate left-sided valve disease, mainly mitral regurgitation (70%) ( Table 1) . Thirty-six patients (33%) had CTS and 11 patients (10%) were considered to have MGUS.
Previous misdiagnosis
Thirty-four patients (35%) had been previously misdiagnosed with other cardiac diseases. Among them, 'hypertensive heart disease' was the most common (12 patients) followed by hypertrohic cardiomyopathy (HCM) (8), ischaemic heart disease (4), heart failure with preserved ejection fraction (HFpEF) (3), aortic stenosis (AS) (3), and miscellanea of other diagnosis (4).
Functional status
Among the overall cohort, the majority of patients were considered to be in NYHA functional class II (54; 50%) at diagnosis, while 19 (17.6%) were asymptomatic from a cardiac point of view at first evaluation ( Table 1) . During follow-up, only a 19% of patients of the entire cohort remained free of HF symptoms and 36% did not require admission for HF or other cardiovascular complications. Table S4 (see Supplementary material online) summarizes the different characteristics according NYHA functional class.
Survival and therapies
During a median follow-up of 13.8 (IQR 4.5-30.5) months after diagnosis, 18 patients died. The majority of them, 15 patients (83%), died due to cardiovascular causes (14 patients (93.3%) due to refractory HF, and 1 patient (6.7%) due to ischaemic stroke), with a mean age of 81.8 ± 6.5 at the time of death. Overall survival at 12, 24 and 36 months was 93% (87-99), 89% (81-97) and 74% (60-88), respectively ( Figure 1) . There was inconclusive evidence that patients with MCF > _30% had better survival than those with MCF <30% [HR 0.83 (0.29-2.36); P = 0.73] and that patients with LVEF <50% had worse survival than those with LVEF > _50% [HR 1.32 (0.48-3.57); P = 0.6].
Mortality was significantly higher in patients who were diagnosed invasively (88.9 vs. 56.7%; P = 0.015) and, as expected, it was associated with a higher rate of HF development (100 vs. 77.8%; P = 0.022), CV admissions (88.9 vs. 58.8%; P = 0.016), worse renal function (40.4 vs. 56.6 mL/min/1.73m 2 ; P < 0.001), and higher NTproBNP values compared with those of survivors (15 617 vs. 2922 pg/mL; P = 0.012). Other findings are shown in Supplementary material online, Table S5 .
In terms of medical therapy, at first evaluation, 45 (42%) patients were receiving ACEI or ARB and 41 (38%) were on beta-blockers. 
Electrocardiographic characteristics
Sixty subjects (56%) had any form of AF and 19 (17%) had a permanent pacemaker. Only 22 patients (22%) fulfilled low QRS voltage according to limb and precordial leads criteria, or 48% considering Sokolow index ( Table 2) .
LV hypertrophy on ECG was only present in 10 patients (11%) and median voltage-to-mass was of 0.17 mV/g/m 2 (0.12-0.26). Only 2 patients (both diagnosed incidentally) had a normal ECG. The commonest finding on ECG (60 patients, 63%) was a pseudo-infarct pattern ( Figure 2 ).
Echocardiographic characteristics
Mean LVEF was 52 ± 14% with 39 patients (37%) showing a LVEF <50%. Median MCF was 30% (IQR 21-43). Mean maximal septum thickness was 17.5 ± 3 mm. The pattern of hypertrophy was symmetric in 81 individuals (76%) and asymmetric in 25 patients (23%) (Figure 3 ). Only one patient (1%) did not show LV hypertrophy > _12 mm. This patient was incidentally diagnosed by a positive DPD. Mean LV mass was 203 ± 69 gr/m 2 and pericardial effusion was present in up to 42% of the patients.
Regarding evaluation of diastolic function, mean early deceleration time was 180 ± 53 ms and only 35% of the patients showed a restrictive filling pattern ( Table 2) .
Discussion
This study describes a large cohort of patients with ATTRwt, including patients diagnosed non-invasively for the first time according to the recently proposed diagnostic criteria. 12 Our study shows that
ATTRwt patients can present with a variety of clinical, electrocardiographic and echocardiographic features. Moreover, it demonstrates that some classic features are rare and others are not as rare as traditionally believed. Consequently, our study highlights that in order to correctly diagnose this condition, physicians should not limit their suspicions only to patients who fit the classic clinical phenotype.
Beyond the classic clinical profile
Previous published ATTRwt series have shown a marked male preponderance in ATTRwt with rates of affected males ranging from 89% to 98% 8, 9 ( Table 3) . No clear explanations have been proposed to support the apparently increased incidence of ATTRwt among men. Furthermore, male sex-predominance in an age-related disease contrasts with increased life expectancy of women in most countries. In our series, almost 20% of patients were female, which is decidedly higher than the anecdotal rate previously reported in ATTRwt. Women were significantly older at time of symptom onset and diagnosis, they were mainly diagnosed non-invasively and presented with increased LVEF, less thicker LV and lower LV mass. These findings may suggest that female ATTRwt patients present later and with a less aggressive profile compared with ATTRwt male patients. Our groups have recently published studies on atypical ATTRwt clinical scenarios.
14,24,25 and we have found a high number of female patients, supporting the hypothesis that the proportion of females affected by ATTRwt could have been largely underestimated. In contrast to previously published series of similar size (Table 3) , our series included patients with a non-invasive diagnosis, which probably allows identification of individuals that do not fulfil the 'classic' phenotype. Interestingly, although not statistically significant, patients diagnosed non-invasively showed a shorter interval to diagnosis.
Contrary to previous reports, comorbidities were frequently found in our series. These entities might have been underrepresented in previous series from referral centres where patients tend to present with a more classical clinical profile 8, 9 ( Table 3) .
Special consideration should be made to high blood pressure.
Hypertensive heart disease was indeed the most common previous misdiagnosis in our cohort. Hypertension is highly prevalent in the elderly population and LVH is frequently attributed to it. ATTRwt should not be excluded in this context and it should be highly suspected when hypertensive patients show normal blood pressure and require dose reduction or discontinuation of antihypertensive drugs. HF is by far the most frequent manifestation of ATTRwt. Nonetheless, the clinical spectrum of ATTRwt is broader (Figure 4) . One third of ATTRwt patients in our series did not present with signs or symptoms of HF at diagnosis ( Table 1) . Some ATTRwt patients presented with advanced AV block, stroke or restrictive cardiomyopathy, and HCM phenocopies. The heterogeneous presentation of ATTRwt is increasingly recognised in the literature and the latest ESC guidelines on HCM have acknowledged the role of bone-tracer scintigraphy for the differential diagnosis of ATTR. 26 More recently, the focus has turned towards the coexistence and importance of ATTRwt in the context of degenerative AS. 25 At the other end of the spectrum, ATTRwt can be diagnosed incidentally after a DPD scan performed for other reasons. Given the high sensitivity of scintigraphy to detect TTR amyloid before abnormalities are identified by other cardiac tests 24, 27 and because new drugs under investigation could be more effective in earlier stages of the disease, DPD scintigraphy is an ideal screening tool for clinical scenarios where the prevalence of ATTRwt is beginning to be significant. 14, 26, 25 Overcoming typical features-disproving the myths
Although low-voltage QRS is widely considered the most characteristic ECG sign of cardiac amyloidosis, 4 we found that this feature can only be found in one fifth of individuals according to the widely used limb and precordial criteria (Figure 4) . Nonetheless, the prevalence of low voltage may vary depending on the criteria applied. 19, 20 A pseudoinfarct pattern (mainly in anterior leads) was the most frequent ECG finding (60% of patients) in our series ( Figure 2 ) and other ATTRwt cohorts have reported similar findings. 13 Moreover, as shown in our cohort, LV hypertrophy criteria can be fulfilled in up to 10% of patients, making ATTRwt diagnosis in everyday practice challenging ( Figure 2) . A normal ECG can also be present in ATTRwt and, in our experience, usually goes hand-in-hand with an incidental bone-tracer cardiac uptake.
From an echocardiographic perspective, the classic ATTRwt phenotype has long been considered to be a thick-walled ventricle with a granular appearance of the myocardium. Despite the fact that a concentric hypertrophic pattern could be considered intuitively as part of the infiltrative nature of cardiac amyloidosis, we have found that almost 25% of patients have an asymmetric pattern of hypertrophy ( Figure 4) . The reported prevalence of asymmetric hypertrophy in cardiac amyloidosis in old series was quite low. However, a higher proportion of asymmetric hypertrophy (up to 69%) has been reported recently in a CMR study with 51 patients with several types of cardiac amyloidosis, 28 and also a segmental form with predominance of deposits in the septum has been described by histology. 29 Moreover, a recent study from the Mayo Clinic 30 described normal wall thickness in 3% of patients diagnosed with cardiac amyloidosis demonstrated by EMB. In this subgroup, 14% of individuals had ATTRwt and all of them required medications for congestive HF. Therefore, normal wall thickness does not exclude the possibility of cardiac amyloid, altering the accepted viewpoint that amyloidotic cardiomyopathy equals increased ventricular wall thickness. Additionally, the requirement of at least mild LVH to support a noninvasive diagnosis might lead to an underestimation of ATTRwt. Regarding systolic function, and notwithstanding the classic strong link between ATTRwt and preserved EF, we found depressed LVEF <50% in ATTRwt more commonly than in other subtypes of cardiac amyloidosis. More than one third of our patients presented with LVEF <50%, and 10 (9%) showed a LVEF <30%. Due to the small sample size, evidence was not conclusive whether impaired LVEF or decreased MCF were associated or not with a reduced survival in our cohort.
Clinical impact of diagnosing ATTRwt
Overall, establishing the diagnosis of ATTRwt is important even in the absence of an approved specific therapy. ATTRwt diagnosis usually leads to modifications in prescribed treatment since betablockers, ACEI, and ARB are usually poorly tolerated in these patients and calcium channel blockers and digitalis are contraindicated. 3, 4 Moreover, intravascular fluid depletion from loop diuretics should always be borne in mind and diuretics used with care. Diagnosis of ATTRwt also leads to close rhythm follow-up as conduction defects could appear frequently and pacemaker insertion could be needed. By contrast, ICD implantation is controversial in ATTRwt for lack of evidence, 4,6,15 making differential diagnosis between ATTRwt and HCM very important. Another consequence of recognising ATTRwt is defining patient prognosis. Survival in ATTRwt is better than in other forms of cardiac amyloidosis and probably better than previously thought (Figure 4) . Although survival in our cohort was 74% at 3 years, it should be noted that our cohort included a significant amount of patients diagnosed non-invasively in whom the diagnosis could have been made earlier, and also patients diagnosed incidentally and in 'atypical' clinical scenarios different to HF, representing an earlier phase of the disease. Finally, it is expected that appropriate diagnosis may have a direct therapeutic impact in the near future given the promising results of ongoing clinical trials with different disease modifying compounds. 16, 17 Limitations Considering the double-centre cohort study, variations in imaging techniques between the two centres cannot be fully excluded. Additionally, data from other biomarkers, speckle tracking or CMR could not be included in the present study due to the lack of standardization between the two centres. Survival data was limited to few events and a relatively short-term follow-up.
A potential heterogeneous nature of patient population due to the different means of diagnosis could not be excluded.
Finally, both participating centres are highly specialized, with active cardiac amyloidosis programmes and referral and survival bias cannot be ruled out.
Conclusions
The clinical spectrum of ATTRwt is heterogeneous and partly differs from the classic clinical phenotype of this disease currently accepted in the literature: women are affected in a significant proportion of cases; asymmetric LV hypertrophy and impaired LVEF are not rare; the commonest ECG finding is a pseudo-infarct pattern and only a minority of patients show low QRS voltages. Clinicians should be aware of the broad clinical spectrum of ATTRwt in order to correctly identify this entity for which a number of disease-modifying treatments are under investigation.
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